Correlation of patient characteristics and tumor histology in patients (pts) with locally advanced cutaneous squamous cell carcinoma (LACSCC) receiving immune checkpoint inhibitor treatment (ICI): A retrospective analysis

被引：0
|
作者：
Frej, Khaoula Ben Haj
Kerr, Phil
Stewart, Campbell
Hegde, Upendra P.
机构：
[1] Univ Connecticut, Sch Med, Farmington, CT USA
[2] Univ Connecticut, Hlth Ctr, Farmington, CT USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e21553
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Response and outcomes with immune checkpoint inhibitor (ICI) in patients (pts) with urothelial carcinoma (UC) and subtype histology (SH)
    Rafailia Bakaloudi, Dimitra
    Makrakis, Dimitrios
    Talukder, Rafee
    Nikolaos Diamantopoulos, Leonidas
    Jindal, Tanya
    Nguyen, Charles B.
    Hobeika, Charbel
    Thomas, Vinay Mathew
    Johnson, Jeffrey
    Marmolejo Castaneda, David Humberto
    Korolewicz, James
    Zakopoulou, Roubini
    Hui, Gavin
    Barata, Pedro C.
    Alonso Buznego, Lucia Andrea
    Brown, Jason R.
    Stewart, Tyler F.
    Epstein, Ilana B.
    Khaki, Ali Raza
    Grivas, Petros
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [2] Immune checkpoint inhibitor therapy for advanced cutaneous squamous cell carcinoma in Australia: a retrospective real world cohort study
    McLean, Luke S.
    Lim, Annette M.
    Bressel, Mathias
    Lee, Jenny
    Ladwa, Rahul
    Guminski, Alexander D.
    Hughes, Brett
    Bowyer, Samantha
    Briscoe, Karen
    Harris, Samuel
    Kukard, Craig
    Zielinski, Rob
    Alamgeer, Muhammad
    Carlino, Matteo
    Mo, Jeremy
    Park, John J.
    Khattak, Muhammad A.
    Day, Fiona
    Rischin, Danny
    MEDICAL JOURNAL OF AUSTRALIA, 2024, 220 (02) : 80 - 90
  • [3] Development of perioperative immune checkpoint inhibitor therapy for locally advanced esophageal squamous cell carcinoma
    Kadono, Toru
    Yamamoto, Shun
    Kato, Ken
    FUTURE ONCOLOGY, 2024, 20 (28) : 2097 - 2107
  • [4] Immune checkpoint inhibition (ICI) in advanced cutaneous squamous cell carcinoma (cSCC): Clinical response and correlative biomarker analysis.
    Park, Jong Chul
    Wirth, Lori J.
    Flaherty, Keith
    Lawrence, Donald P.
    Demehri, Shadmehr
    Kraft, Stefan
    Foreman, Ruth
    Clark, John R.
    Cohen, Justine Vanessa
    Kim, Yuhree
    Boland, Genevieve Marie
    Frederick, Dennie Tompers
    Sullivan, Ryan J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [5] Patients (pts) with advanced hepatocellular carcinoma (HCC) with long-term response to immune checkpoint inhibitor (ICI) therapy
    Keane, F.
    Cowzer, D.
    Khalil, D.
    Shia, J.
    Do, R.
    Folorunso, S.
    El Dika, I.
    Yaqubie, A.
    Kim, T.
    O'Reilly, E.
    Abou-Alfa, G.
    Harding, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S111 - S112
  • [6] Association of radiographic and pathologic outcomes in patients (pts) with advanced renal cell carcinoma (RCC) with and without thrombus receiving preoperative immune checkpoint inhibitor (ICI) regimens and circulating biomarkers
    Issa, Wadih
    Gunenc, Damla
    Zhang, Song
    Zhou, Qinhan
    Gerald, Thomas
    Tachibana, Isamu
    Bhanvadia, Raj Ramnik
    Kapur, Payal
    Woldu, Solomon L.
    Lotan, Yair
    Cadeddu, Jeffrey A.
    Gaston, Kris
    Qin, Qian
    Brugarolas, James
    Hammers, Hans J.
    Wang, Andrew Zhuang
    Margulis, Vitaly
    Zhang, Tian
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 415 - 415
  • [7] Immune checkpoint inhibitor (ICI) treatment in advanced melanoma (aMel) patients (pts) with renal or hepatic dysfunction (dysf): Real-world patient characteristics and outcomes.
    Spillane, Susan
    Abernethy, Amy Pickar
    Brown, Nicholas R.
    Freedman, Andrew N.
    Lenis, David
    Maignan, Kathleen
    Mariotto, Angela
    Miksad, Rebecca A.
    Torres, Aracelis Z.
    Sharon, Elad
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [8] Evaluating safety and efficacy of immune checkpoint inhibitors (ICI) in elderly patients (pts) for advanced cancer treatment: A retrospective study
    Brixius, S. J.
    Meiss, F.
    von Bubnoff, D.
    Zeiser, R.
    Waller, C. F.
    Duyster, J.
    Rawluk, J.
    ANNALS OF ONCOLOGY, 2018, 29
  • [9] Role of tumor mutational burden (TMB) and microsatellite instability (MSI) in patients (pts) with advanced urothelial carcinoma (aUC) treated with immune checkpoint inhibitor (ICI)
    Bakaloudi, Dimitra Rafailia
    Talukder, Rafee
    Makrakis, Dimitrios
    Diamantopoulos, Leonidas Nikolaos
    Patgunarajah, Ubenthira
    Thomas, Vinay Mathew
    Jindal, Tanya
    Brown, Jason R.
    Miletic, Marija
    Johnson, Jeffrey
    Hui, Gavin
    Buznego, Lucia Alonso
    Morales-Barrera, Rafael
    Castaneda, David Humberto Marmolejo
    Nguyen, Charles B.
    Barata, Pedro C.
    Stewart, Tyler F.
    Gupta, Shilpa
    Grivas, Petros
    Khaki, Ali Raza
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 654 - 654
  • [10] Antibiotics use decreases survival in cutaneous squamous cell carcinoma patients receiving immune checkpoint inhibitors
    Bonnefin, C.
    Schneider, S.
    Gerard, E.
    Dutriaux, C.
    Ferte, T.
    Prey, S.
    Guicheney, M.
    Ducharme, O.
    Pedeboscq, S.
    Beylot-Barry, M.
    Pham-Ledard, A.
    EUROPEAN JOURNAL OF CANCER, 2025, 217
12345